Lymphoma Cancer

What Certain Patients with DLBCL Need To Know About Monjuvi-Revlimid

September 14th 2020, 3:00pm

Patients with relapsed/refractory diffuse large B-cell lymphoma who are unable to undergo autologous stem cell transplant have a new treatment option in the combination of Monjuvi and Revlimid. The lead researcher on the study that led to the combination’s approval discusses what patients need to know.

CURE® Speaking Out Video Series Supports Blood Cancer Awareness Month and World Lymphoma Awareness Day

September 10th 2020, 9:00pm

Susan M. O’Brien, M.D., one of the nation’s foremost leukemia experts, discusses the future of frontline therapies and upcoming clinical trials associated with chronic lymphocytic leukemia.

Monjuvi-Revlimid Combination Approval Fills Unmet Need for Certain Patients with DLBCL

September 4th 2020, 6:00pm

A recent approval of the combination of Monjuvi and Revlimid fills an unmet need for certain patients with DLBCL, according to Dr. Gilles Salles.

Intensifying Rituxan for Diffuse Large B-Cell Lymphoma Treatment Does Not Improve Health Outcomes

September 2nd 2020, 9:00pm

Heightening the dose of the targeted drug Rituxan (rituximab) during the first four cycles of the R-CHOP regimen does not improve outcomes in treating patients with diffuse large B-cell lymphoma, the phase 3 HOVON-84 trial found.

5 Reports on Lymphoma Patients May Have Missed

August 31st 2020, 1:00pm

CURE® compiled a roundup of five recent reports patients with lymphoma may have missed.

Enzastaurin May Show Benefit in Subgroup of Patients with Diffuse Large B-Cell Lymphoma

August 25th 2020, 9:00pm

The agent, in combination with the current standard of care, is being evaluated as a frontline treatment for patients with high-risk Denovo Genomic Marker 1 (DGM1)–positive DLBCL.

FDA Provides Updated Analysis of Breast Implant-Associated Lymphoma, Breast Implant Illness

August 21st 2020, 6:00pm

The FDA also released a video for patients that details seven things they should know about breast implants, including information about breast implant-associated lymphoma and systemic symptoms.

Understanding Relapsed/Refractory Follicular Lymphoma

August 14th 2020, 4:00am

Muscle Mass and Density Could Factor Into Treatment Decisions and Survival for Some Patients with Lymphoma

August 14th 2020, 4:00am

In patients with diffuse large B-cell lymphoma, low muscle mass (LMM) and low muscle density (LMD) could play a role when deciding what kind of treatment option to pursue, and could also impact a patient’s odds of survival, according to a recent study.

Novel CAR T-Cell Therapy Shows Promise in Advanced Hodgkin Lymphoma

August 14th 2020, 4:00am

“Unlike other CAR T-cell therapies, clinical success was not associated with significant complications from therapy,” said Dr. Jonathan Serody. “This means this treatment should be available to patients in a clinic setting and would not require patients to be hospitalized, which is critical in our current environment.”